EMA — authorised 15 November 2022
- Marketing authorisation holder: GENZYME EUROPE BV
- Status: approved
🇪🇺 Enjaymo in European Union
EMA authorised Enjaymo on 15 November 2022
Marketing authorisations
EMA — authorised 15 November 2022
- Application: EMEA/H/C/005776
- Marketing authorisation holder: Recordati Rare Diseases
- Local brand name: Enjaymo
- Indication: Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).
- Pathway: orphan
- Status: approved
Enjaymo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in European Union
Frequently asked questions
Is Enjaymo approved in European Union?
Yes. EMA authorised it on 15 November 2022; EMA authorised it on 15 November 2022.
Who is the marketing authorisation holder for Enjaymo in European Union?
GENZYME EUROPE BV holds the EU marketing authorisation.